Surmodics, Inc. (NASDAQ:SRDX) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations And Financial Condition.

On April 27, 2017, Surmodics, Inc. (the Company) issued a
press release (the Press Release) announcing the results
for the quarter ended March 31, 2017. A copy of the full text of
the Press Release is furnished as Exhibit 99.1 to this report.

The information contained in this Item 2.02, including Exhibit
99.1, shall not be deemed to be filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, nor shall
they be deemed to be incorporated by reference into any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

About Surmodics, Inc. (NASDAQ:SRDX)

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Surmodics, Inc. (NASDAQ:SRDX) Recent Trading Information

Surmodics, Inc. (NASDAQ:SRDX) closed its last trading session up +0.65 at 24.80 with 60,737 shares trading hands.